

# Magnesium sulphate for the treatment of pre-eclampsia: a trial to evaluate the effects on women and babies

|  |   |  |
|--|---|--|
| <b>Submission date</b><br>25/10/2000   | <b>Recruitment status</b><br>No longer recruiting     | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>25/10/2000 | <b>Overall study status</b><br>Completed              | <input type="checkbox"/> Protocol                    |
| <b>Last Edited</b><br>09/07/2014       | <b>Condition category</b><br>Pregnancy and Childbirth | <input type="checkbox"/> Statistical analysis plan   |
|  |   | <input checked="" type="checkbox"/> Results          |
|  |   | <input type="checkbox"/> Individual participant data |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Lelia Duley

**Contact details**  
MAGPIE Trial Co-ordinating Centre  
Institute of Health Sciences  
Old Road  
Headington  
Oxford  
United Kingdom  
OX3 7LF

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
G9701680

# Study information

## Scientific Title

## Acronym

MAGPIE

## Study objectives

To determine the effect of magnesium sulphate when used for women with pre-eclampsia on the risk of eclampsia and perinatal death. In addition, to determine the effects of other measures of important morbidity and on use of health services resources.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Pre-eclampsia

## Interventions

Magnesium sulphate/placebo.

Follow-up: until discharge following delivery. Four year follow-up of the children is planned.

## Intervention Type

Other

## Phase

Not Applicable

**Primary outcome measure**

1. Eclampsia
2. Death of the baby.

**Secondary outcome measures**

1. Maternal death
2. Serious maternal morbidity
3. Labour and delivery outcomes
4. Use of maternal health services
5. Serious neonatal morbidity
6. Use of neonatal health services

**Overall study start date**

01/01/1998

**Completion date**

31/01/2005

## **Eligibility**

**Key inclusion criteria**

1. Not delivered, or delivered within the last 24 hours
2. Blood pressure today is  $\geq 90$  mmHg diastolic or  $\geq 140$  mmHg systolic, on at least two occasions
3. Proteinuria of at least 1+
4. There is clinical uncertainty about whether magnesium sulphate would be beneficial (factors likely to influence this uncertainty are the presence of any of the following: hypereflexia, frontal headache, abnormal liver function or coagulation, and epigastric tenderness)

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

10141

**Key exclusion criteria**

The woman does not wish to be randomised, for whatever reason/the attending clinician believes magnesium sulphate should either be given or withheld/hypersensitivity to magnesium /renal failure (women who have renal impairment may be randomised, but the volume of allocated treatment should be halved for each dose)/hepatic coma if risk of renal failure /myaesthesia gravis.

**Date of first enrolment**

01/01/1998

**Date of final enrolment**

31/01/2005

## **Locations**

**Countries of recruitment**

Albania

Argentina

Australia

Bangladesh

Brazil

Colombia

Cuba

Egypt

England

Ghana

India

Malawi

Nigeria

Pakistan

Sierra Leone

Singapore

South Africa

United Kingdom

United States of America

Zimbabwe

**Study participating centre**

**MAGPIE Trial Co-ordinating Centre**  
Oxford  
United Kingdom  
OX3 7LF

## Sponsor information

### Organisation

Medical Research Council (MRC) (UK)

### Sponsor details

20 Park Crescent  
London  
United Kingdom  
W1B 1AL  
+44 (0)20 7636 5422  
[clinical.trial@headoffice.mrc.ac.uk](mailto:clinical.trial@headoffice.mrc.ac.uk)

### Sponsor type

Research council

### Website

<http://www.mrc.ac.uk>

## Funder(s)

### Funder type

Research council

### Funder Name

Medical Research Council (MRC) (UK)

### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 01/06/2002   |            | Yes            | No              |
| <a href="#">Results article</a> | results | 08/03/2004   |            | Yes            | No              |
| <a href="#">Results article</a> | results | 01/03/2007   |            | Yes            | No              |
| <a href="#">Results article</a> | results | 14/04/2009   |            | Yes            | No              |